Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
8 Analysts Have This to Say About ACADIA Pharmaceuticals
05:31pm, Friday, 05'th Aug 2022 Benzinga
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
02:43pm, Friday, 05'th Aug 2022 Benzinga
Upgrades
For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. At the moment
Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates
12:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia: Powerful Unfolding Catalysts
06:08am, Wednesday, 03'rd Aug 2022
Aside from being launched for Parkinson's, Nuplazid is potentially gaining two additional label expansions. Trofinetide is also poised to gain FDA approval to treat the rare condition, Rett syndrome a
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:37am, Monday, 01'st Aug 2022
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
04:05pm, Monday, 25'th Jul 2022
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S.
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
03:22pm, Tuesday, 19'th Jul 2022 Zacks Investment Research
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
01:09pm, Tuesday, 19'th Jul 2022
Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
03:14pm, Friday, 08'th Jul 2022 Zacks Investment Research
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
12:25pm, Friday, 08'th Jul 2022
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.
FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
06:08pm, Wednesday, 29'th Jun 2022
Acadia won approval for its only commercialized drug Nuplazid in 2017 and has tried and failed to expand its label since. This month an FDA AdComm voted against an approval in Alzheimer's disease psyc
3 Big Ideas From Citigroup With Up to 80% Upside
12:38pm, Wednesday, 22'nd Jun 2022
As markets figure out a direction over the course of this summer, economic headwinds may be holding back some gains.
Why Acadia Pharmaceuticals Stock Is Crashing Today
04:07pm, Tuesday, 21'st Jun 2022 The Motley Fool
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
02:58pm, Tuesday, 21'st Jun 2022
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.
